Gain Therapeutics (GANX) Operating Expenses (2020 - 2026)
Gain Therapeutics (GANX) posted quarterly Operating Expenses of $5.4 million for Q1 2026, up 22.52% year-over-year from $4.4 million in Q1 2025, and up 19.87% quarter-over-quarter from $4.5 million in Q4 2025.
Gain Therapeutics (GANX) Operating Expenses (2020 - 2026) Analysis & Trends
Gain Therapeutics' Operating Expenses history runs 7 years deep, the most recent figure standing at $5.4 million for Q1 2026.
- In Q1 2026, Operating Expenses rose 22.52% year-over-year to $5.4 million; the TTM figure through Mar 2026 stood at $19.7 million (down 3.18% YoY), while the FY2025 annual figure was $18.7 million, down 8.06% from the prior year.
- Operating Expenses for Q1 2026 stood at $5.4 million, up from $4.5 million in the prior quarter.
- The five-year high for Operating Expenses was $8.2 million in Q2 2024, with the low at $3.3 million in Q4 2024.
- The 5-year median for Operating Expenses is $4.8 million (2022), against an average of $5.0 million.
- The sharpest annual moves came in 2023 and 2025: Operating Expenses jumped 58.54% in 2023, then sank 37.8% in 2025.
- Gain Therapeutics' Operating Expenses stood at $4.6 million in 2022, then retreated by 3.38% to $4.4 million in 2023, then retreated by 24.42% to $3.3 million in 2024, then surged by 34.07% to $4.5 million in 2025, then climbed by 19.87% to $5.4 million in 2026.
- Business Quant data shows GANX's Operating Expenses at $5.4 million in Q1 2026, $4.5 million in Q4 2025, and $4.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | Gain Therapeutics | 85.12 Mn | 85.12 Mn | - | 4.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.68 Mn |
| Mar 31, 2026 | 5.35 Mn |
| Dec 31, 2025 | 4.47 Mn |
| Sep 30, 2025 | 4.79 Mn |
| Jun 30, 2025 | 5.09 Mn |
| Mar 31, 2025 | 4.37 Mn |
| Dec 31, 2024 | 3.33 Mn |
| Sep 30, 2024 | 4.46 Mn |
| Jun 30, 2024 | 8.18 Mn |
| Mar 31, 2024 | 4.38 Mn |
| Dec 31, 2023 | 4.41 Mn |
| Sep 30, 2023 | 4.89 Mn |
| Jun 30, 2023 | 7.73 Mn |
| Mar 31, 2023 | 5.28 Mn |
| Dec 31, 2022 | 4.56 Mn |
| Sep 30, 2022 | 4.75 Mn |
| Jun 30, 2022 | 5.27 Mn |
| Mar 31, 2022 | 3.33 Mn |
| Dec 31, 2021 | 3.25 Mn |
| Sep 30, 2021 | 4.66 Mn |